Mircera Injection, Solution
NDC Package 59353-408-09

11-digit billing NDC: 59353040809

Package Information

Mircera (methoxy polyethylene glycol-epoetin beta) injection is mircera is contraindicated in patients with:•Uncontrolled hypertension [see Warnings and Precautions (5.3)]•Pure red cell aplasia (PRCA) that begins after treatment with Mircera or other erythropoietin protein drugs [see Warnings and Precautions (5.6)]•History of serious or severe allergic reactions to Mircera (e.g., anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria) [see Warnings and Precautions (5.7, 5.8)]. This formulation utilizes a injection, solution delivery system. Marketed by Vifor (international) Inc., this product is identified by NDC 59353-408 and is authorized under FDA application BLA125164.

Identification & Billing

NDC Package Code
59353-408-09
Package Description
1 SYRINGE, GLASS in 1 CARTON / 1 mL in 1 SYRINGE, GLASS
Product Code
11-Digit Billing Format
59353040809
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Mircera
Non-Proprietary Name
Methoxy Polyethylene Glycol-epoetin Beta
Substance Name
Methoxy Polyethylene Glycol-epoetin Beta
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intravenous - Administration within or into a vein or veins.
Usage Information
Mircera is contraindicated in patients with:•Uncontrolled hypertension [see Warnings and Precautions (5.3)]•Pure red cell aplasia (PRCA) that begins after treatment with Mircera or other erythropoietin protein drugs [see Warnings and Precautions (5.6)]•History of serious or severe allergic reactions to Mircera (e.g., anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria) [see Warnings and Precautions (5.7, 5.8)].

Regulatory & Marketing

Labeler Name
Vifor (international) Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA125164
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
10-24-2014
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 59353-408-09 identifies a specific commercial package of 1 syringe, glass in 1 carton / 1 ml in 1 syringe, glass of Mircera, a human prescription drug labeled by Vifor (international) Inc.. This injection, solution is formulated for intravenous use and contains methoxy polyethylene glycol-epoetin beta as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Vifor (international) Inc. on October 24, 2014. The current certification is valid through December 31, 2027.

How is this Vifor (international) Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 59353040809. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
59353-408-09
11-Digit CMS (5-4-2)
59353-0408-09

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.